“The decision to enter into this new agreement was based on the progress of our current research, which has been focused on synthesizing certain insulin enhancing or mimetic polyphenolic compounds that improve insulin function by a factor of 20 in laboratory tests,” said Mr Harmel Rayat, president and CEO of PhytoMedical Technologies.
In addition to being associated with diabetes, insulin function, or the lack thereof, is now known to be linked with a number of other ailments, including Alzheimer’s disease. As such, the company is investigating the possibility of developing the compound in this indication.